Case Reports
doi: 10.1001/archdermatol.2011.274.
Successful long-term use of intravenous immunoglobulin to treat livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity
- PMID: 22006147
- DOI: 10.1001/archdermatol.2011.274
Item in Clipboard
Case Reports
Successful long-term use of intravenous immunoglobulin to treat livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity
Arch Dermatol.
2011 Oct.
No abstract available
Similar articles
-
Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) treated successfully with tissue plasminogen activator.Arch Dermatol. 2006 Nov;142(11):1466-9. doi: 10.1001/archderm.142.11.1466. Arch Dermatol. 2006. PMID: 17116837
-
Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) and prothrombin G20210A heterozygosity: response to t-PA therapy.Acta Derm Venereol. 2010;90(1):91-2. doi: 10.2340/00015555-0760. Acta Derm Venereol. 2010. PMID: 20107738 No abstract available.
-
Treatment of livedoid vasculopathy with short-cycle intravenous immunoglobulins.Acta Derm Venereol. 2005;85(4):374-5. doi: 10.1080/00015550510027865. Acta Derm Venereol. 2005. PMID: 16191872 No abstract available.
-
[Use of intravenous immunoglobulin in neurological disorders].Rev Med Suisse. 2005 Apr 27;1(17):1167-70. Rev Med Suisse. 2005. PMID: 15941089 Review. French.
-
Livedoid vasculopathy: A review of pathogenesis and principles of management.Indian J Dermatol Venereol Leprol. 2016 Sep-Oct;82(5):478-88. doi: 10.4103/0378-6323.183635. Indian J Dermatol Venereol Leprol. 2016. PMID: 27297279 Review.
Cited by
-
Efficacy and safety of intravenous immunoglobulin for treating refractory livedoid vasculopathy: a systematic review.Ther Adv Chronic Dis. 2022 May 22;13:20406223221097331. doi: 10.1177/20406223221097331. eCollection 2022. Ther Adv Chronic Dis. 2022. PMID: 35634570 Free PMC article. Review.
-
Livedoid vasculopathy: A multidisciplinary clinical approach to diagnosis and management.Int J Womens Dermatol. 2021 Sep 2;7(5Part A):588-599. doi: 10.1016/j.ijwd.2021.08.013. eCollection 2021 Dec. Int J Womens Dermatol. 2021. PMID: 35024414 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
